US 7855276
Framework residue substituted humanized COL-1 antibodies and their use
granted A61KA61K2039/505A61P
Quick answer
US patent 7855276 (Framework residue substituted humanized COL-1 antibodies and their use) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Dec 21 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 47
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00